Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price rose 8.8% on Wednesday . The company traded as high as C$9.27 and last traded at C$9.25. 404 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 1,197 shares. The stock had previously closed at C$8.50.
Devonian Health Group Price Performance
The stock has a fifty day simple moving average of C$9.45 and a 200-day simple moving average of C$10.95. The company has a market capitalization of C$25.72 million, a PE ratio of -4.11 and a beta of 0.44. The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Featured Stories
- Five stocks we like better than Devonian Health Group
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
